Psychemedics Corp stock (US7444221033): Recent ticker change and delisting

Psychemedics Corp (PMD) underwent a ticker change to PMDI and delisting to OTC markets, impacting trading availability for US investors as reported by Robinhood on recent corporate actions.

Psychemedics Corp, a company specializing in hair-based drug testing services, recently executed a ticker symbol change from PMD to PMDI and was delisted from Nasdaq to over-the-counter (OTC) markets. The security is now set to Position Closing Only (PCO), limiting new positions for investors, according to Robinhood as of May 2026. This move follows standard procedures for certain corporate actions in the biotech sector.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Psychemedics Corporation
• Sector/industry: Health Care / Medical Laboratories
• Headquarters/country: United States
• Core markets: Workplace drug testing, primarily US
• Home exchange/listing venue: OTC (PMDI)
• Trading currency: USD

Psychemedics Corp: core business model

Psychemedics Corp develops and provides proprietary hair forensic testing products for detecting drugs of abuse. The company's technology analyzes hair samples to provide up to 90 days of reliable drug history, offering advantages over traditional urine or blood tests for employers and law enforcement. Headquartered in the US, it serves corporate clients, government agencies, and rehabilitation programs with scalable testing solutions.

The business model centers on laboratory services, with revenue from sample processing fees. Psychemedics operates FDA-cleared labs and holds patents on its hair testing methods, positioning it in the niche forensic toxicology market relevant to US workplace safety regulations.

Main revenue and product drivers for Psychemedics Corp

Primary revenue stems from workplace drug testing contracts, accounting for the majority of income as per historical filings. Key products include tests for substances like marijuana, cocaine, and opioids, with expansions into synthetic drugs. The company targets Fortune 500 firms and public sector clients, benefiting from US demand for pre-employment and random screening.

Industry trends and competitive position

The medical laboratories sector, including drug testing, grows with US opioid crisis responses and workplace safety mandates. Psychemedics differentiates via hair testing's longer detection window, competing with urine-focused peers like Quest Diagnostics. OTC status may limit visibility but retains access for US retail investors via alternative markets.

Why Psychemedics Corp matters for US investors

Listed on US markets with exposure to domestic drug testing demand, Psychemedics offers retail investors a play on health compliance trends amid regulatory pushes like DOT testing rules. OTC trading maintains accessibility despite delisting, with relevance to broader biotech and diagnostics sectors.

Conclusion

The recent ticker change and OTC transition for Psychemedics Corp reflect ongoing corporate adjustments in the health testing space. While trading restrictions apply, the company's core hair testing technology continues to serve key US markets. Investors should monitor IR updates for further developments amid sector dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.